Semnur Pharmaceuticals, Inc. - 10-Q Filing

Semnur Pharmaceuticals reports Q3 2025 financial results amid ongoing merger and debt restructuring activities with Scilex Holding Company.

SEC EDGAR ·

Tickers: $SMNR

Read the full article at SEC EDGAR

More Regulatory news